The Phase 3 clinical trial (NCT06323161) for CagriSema (Cagrilintide B and Semaglutide I), investigating its effects in people with Type 2 Diabetes, reached primary completion on 2025-09-09. This study aimed to assess how much CagriSema lowers blood sugar and body weight compared to placebo.

Background

CagriSema is an investigational medicine combining cagrilintide and semaglutide. It is being studied for the treatment of Type 2 Diabetes, a chronic condition characterized by high blood sugar levels. Semaglutide, one of the components, is already known for its role in managing Type 2 Diabetes and weight.

Trial design

The study, identified as NCT06323161, is a Phase 3 trial titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin." It enrolled 274 participants diagnosed with Type 2 Diabetes. The trial compared CagriSema to a placebo, with participants continuing their existing diabetes medication, which included once-daily basal insulin with or without metformin. The study aimed to assess the extent to which CagriSema lowers blood sugar and body weight.

What this means

The primary completion of this Phase 3 trial signifies that all participants have completed the final data collection for the primary outcome measures. While specific results are not yet available, the completion of this stage is a crucial step in the development of CagriSema. The data collected will be analyzed to determine the efficacy and safety profile of CagriSema in managing blood sugar and body weight in people with Type 2 Diabetes, potentially informing future regulatory submissions and treatment guidelines.

Source

The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06323161, titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin," was posted on 2025-09-09 on clinicaltrials.gov.